Intended for healthcare professionals

Rapid response to:

News

Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots

BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n699 (Published 11 March 2021) Cite this as: BMJ 2021;372:n699

Read our latest coverage of the coronavirus outbreak

Rapid Response:

COVID-19 vaccine, immune respose, previous asymptomatic infection and blood clots

Dear Editor,
The blood clots formation after COVID-19 vaccination is an interesting issue [1]. Regarding the thrombosis triad, the effect of vaccine might be on blood viscosity. The post vaccination stimulaion of immuneresponse might relate to the problem. In a recent report, a person with evidence of previous infection has a significant more immune response [2]. This might be a possible cause of hyperviscosity, an important component of thrombogenesis. Anyone with underlying vascular disase should be carefully evaluated before vaccination. It is also questionable whethere there should be a prevaccination screeening for SARS VoV2 antibody.

Conflict of interest
none

References
1. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots
BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n699
2.Saadat S, Tehrani ZR, Logue J, Newman M, Frieman MB, Harris AD, Sajadi MM. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA. . doi:10.1001/jama.2021.3341

Competing interests: No competing interests

14 March 2021
viroj wiwanitkit
medical professor
Dr DY Patil university, Pune, India
Dr DY Patil University, Pune, India